↓ Skip to main content

Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

Overview of attention for article published in Molecular Cancer Therapeutics, September 2020
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news
1 news outlet
twitter
4 tweeters
reddit
1 Redditor

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
9 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I
Published in
Molecular Cancer Therapeutics, September 2020
DOI 10.1158/1535-7163.mct-20-0103
Pubmed ID
Authors

Nicolas Floc'h, Sangbin Lim, Sue Bickerton, Afshan Ahmed, Jonathan Orme, Jelena Urosevic, Matthew J. Martin, Darren A.E. Cross, Byoung Chul Cho, Paul D. Smith

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 9 100%

Demographic breakdown

Readers by professional status Count As %
Other 3 33%
Student > Master 2 22%
Student > Postgraduate 1 11%
Student > Ph. D. Student 1 11%
Unknown 2 22%
Readers by discipline Count As %
Medicine and Dentistry 2 22%
Biochemistry, Genetics and Molecular Biology 1 11%
Pharmacology, Toxicology and Pharmaceutical Science 1 11%
Immunology and Microbiology 1 11%
Chemical Engineering 1 11%
Other 0 0%
Unknown 3 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 July 2021.
All research outputs
#2,076,090
of 18,694,771 outputs
Outputs from Molecular Cancer Therapeutics
#292
of 3,341 outputs
Outputs of similar age
#56,421
of 320,419 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#5
of 49 outputs
Altmetric has tracked 18,694,771 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,341 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,419 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.